Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022

[Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial

Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?

Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions

Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy

Poster presentation at the annual meeting of the Association for Cancer Immunotherapy

Poster presentation at the International Symposium on Pediatric Neuro-Oncology

A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients